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Follicular lymphoma (FL) is an incurable B cell 
lymphoma that is diagnosed in 18,000 Ameri-
cans and has a worldwide incidence of 120,000 
cases per year. The clinical behavior of FLs is 
characterized by slow and relentless growth with 
inevitable relapses despite intensive chemother-
apy, and eventually 50% progress toward an ag-
gressive disease that resembles diffuse large B cell 
lymphoma (DLBCL). Genetically, FLs are char-
acterized by the translocation t(14;18) that ac-
tivates the anti-apoptotic BCL2 protein, and it 
is clear that additional lesions are required 
(Staudt, 2007). Accordingly, recent studies have 
cataloged a large number of genomic lesions 
in FL with increasing resolution and precision 
(e.g., Morin et al., 2011; Bouska et al., 2014; 
Okosun et al., 2014; Pasqualucci et al., 2014), 
and studies on serial samples have identified 
chromatin modifiers (e.g., EZH2 and CREBBP) 
as early targets followed by the acquisition of 
additional lesions as the disease evolves (Bödör 
et al., 2013; Green et al., 2013).
Loss of proliferation control is a hallmark of 
cancer and is also seen in aggressive B cell malig-
nancies like mantle cell lymphoma, transformed 
FL, and DLBCL (Morin et al., 2011; Okosun 
et al., 2014; Pasqualucci et al., 2014). In contrast, 
in the indolent stages of FL, disruption of cell 
cycle checkpoints (e.g., p16 or RB1) is considered 
a rare event and mostly linked to disease trans-
formation (Pinyol et al., 1998; Pasqualucci et al., 
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Loss of cell cycle controls is a hallmark of cancer and has a well-established role in aggres-
sive B cell malignancies. However, the role of such lesions in indolent follicular lymphoma 
(FL) is unclear and individual lesions have been observed with low frequency. By analyzing 
genomic data from two large cohorts of indolent FLs, we identify a pattern of mutually 
exclusive (P = 0.003) genomic lesions that impair the retinoblastoma (RB) pathway in nearly 
50% of FLs. These alterations include homozygous and heterozygous deletions of the p16/
CDKN2a/b (7%) and RB1 (12%) loci, and more frequent gains of chromosome 12 that 
include CDK4 (29%). These aberrations are associated with high-risk disease by the FL 
prognostic index (FLIPI), and studies in a murine FL model confirm their pathogenic role in 
indolent FL. Increased CDK4 kinase activity toward RB1 is readily measured in tumor samples 
and indicates an opportunity for CDK4 inhibition. We find that dual CDK4 and BCL2 inhibi-
tor treatment is safe and effective against available models of FL. In summary, frequent RB 
pathway lesions in indolent, high-risk FLs indicate an untapped therapeutic opportunity.
© 2014 Oricchio et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/ 
by-nc-sa/3.0/).
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In the present study, we examine the role of these lesions 
in lymphomagenesis and patient risk, and explore therapeu-
tic implications.
RESULTS
Analysis of array-CGH data from two  
independent cohorts of indolent FLs
The first dataset consists of 64 FL samples collected at the 
Memorial Sloan-Kettering Cancer Center (MSKCC; Fig. 1 A 
and Table S1; data are deposited in GEO under accession no. 
GSE40989). The second dataset includes 198 samples col-
lected at University of Nebraska (Bouska et al., 2014; Fig. 1 B 
and Table S1). Using the GISTIC algorithm (Beroukhim 
et al., 2010; Mermel et al., 2011), we identified 9 statistically 
significant amplified regions and 18 deleted regions in first 
dataset (Table S1), and 26 amplified and 26 deleted regions in 
2014). This view has clinical consequences and, for example, 
the use of cell cycle–directed therapeutics is not typically 
considered at this stage (Fry et al., 2004; Relander et al., 2010; 
Flaherty et al., 2012).
Significantly linked—mutually exclusive or co-occurring— 
genetic lesions can provide insight into the genetic drivers 
of cancers. For example, mutual exclusivity between lesions 
suggests that they target either redundant or incompatible 
functions and this knowledge can help define the function-
ally relevant targets of complex aberrations. For example, 
in the present study we observe a mutually exclusive rela-
tion between lesions affecting the p16/CDKN2A locus, the 
retinoblastoma (RB) locus, and larger gains affecting chro-
mosome 12q13. The association suggests that a cell cycle 
regulator may be a target of the Chr. 12q13 gain, and no-
tably the amplicon always includes the RB1 kinase CDK4. 
Figure 1. Cell cycle control genes are targets of significantly mutual exclusive genomic lesions in FL. (A and B) Analysis of recurrent copy num-
ber changes with GISTIC algorithm identifies statistically significant focally amplified (red) and deleted (blue) regions in 64 FLs (MSKCC cohort; A) and 198 
FLs (UNMC cohort). The height of each peak is proportional to the corresponding q-value. (C–E) mRNA expression of CDK4 (C; *, P = 0.05), RB1 (D; *, P = 0.03), 
and CDKN2A (E; P = 0.24) in diploid cases versus FLs harboring gains on samples from the MSK cohort. The boxplot whiskers extend from the lowest to 
the highest gene expression level in FL patients excluding outliers. P-values were calculated by ANOVA test. (F) Genome-wide analysis for significantly 
linked aberrations in 262 FLs from both cohorts reveals a significant mutually exclusive relation between lesions affecting CDKN2A/B, RB1, and CDK4  
(p = 0.003) P-value was derived by constrained permutation of the alteration set.
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changes. The analysis is based on a mutual exclusivity module 
(MEMo; Ciriello et al., 2012) and described in detail in the 
Materials and methods. We merged the list of copy number 
altered regions and the total now includes all 262 patient sam-
ples. Strikingly, among the most significantly linked mutually 
exclusive events were three chromosomal changes affecting 
key cell cycle control loci (FDR corrected p-value = 0.003) in 
109/262 (42%) of the samples (Fig. 1 F and Table S2). In detail, 
the mutually exclusive lesions were: first, an amplified peak 
(seen in 29%) that affected chromosome 12, and within the peak, 
CDK4 as the most frequently altered gene (Fig. 1, A and B); 
the second dataset (Table S1). As expected, the greater number 
of samples in the second dataset (198 samples versus 64 sam-
ples) enhances the statistical power and enables detection of a 
larger number of significantly recurrent regions. Comparing 
the copy number analysis of the two datasets, we found that 
67% of the regions in the first dataset have a match in the sec-
ond dataset; notably, all significant regions from the two data-
sets (residual q < 14) are matched, indicating a remarkable 
similarity between these two series of indolent FL samples.
Next, we used an unbiased and genome-wide approach 
to identify significant relationships between chromosomal 
Figure 2. Cyclin D3 is mutated in 6% of  
indolent FL. (A) mRNA levels of CCND1, CCND2, and 
CCND3 in 72 FL samples. The boxplot whiskers extend 
from the lowest to the highest gene expression level 
in FL patients excluding outliers. (B) Graphical repre-
sentation of CCND3 mutations in FL. (C) Representa-
tive sequencing traces of homozygous (#I07-2124) 
and heterozygous (#1125P-I06-1301) CCND3 muta-
tions in FL. (D–F) Immunoblot on lysates of 293T (D) 
or FL5-12 pre–B cells (E) expressing the indicated 
wild-type or mutant forms of CYCLIN D3 and either 
untreated or treated for the indicated times with 
cycloheximide (CHX). A quantification of the immuno-
blot results is shown in F. (G) Comparison of the  
frequency of CDKN2A, RB, and CDK4 lesions in indo-
lent (FL) and transformed FLs (tFL).
Table 1. Cell cycle lesions are associated with patient risk by FLIPI
FL classification Diploid Gain/Loss Total (%)
A
FLIPI low 20 6 26 (45)
FLIPI intermediate 6 9 15 (26)
FLIPI high 4 13 17 (29)
B
Grade 1 8 9 17 (29)
Grade 2 10 8 18 (31)
Grade 3A/B 12 11 23 (39)
(A) Cell cycle lesions are significantly associated with high-risk by FLIPI. P = 0.002. (B) Lesions affecting CDK4, RB1, and CDKN2a/b occur across all FL grades without predilection. P = 0.08.
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MSKCC cohort also provides information on histological 
grade and all grades of indolent FL are present. Consistent with 
prior studies (Martin et al., 1995; Hans et al., 2003; Hsi et al., 
2004), we find no association between grade and outcomes 
(P = 0.74), and notably cell cycle lesions were equally distrib-
uted across all grades (P = 0.9; Table 1, B). Hence, genomic 
lesions affecting the CDKN2A, RB, and CDK4 loci are sig-
nificantly enriched among high-risk FL patients.
Immunohistochemistry confirms frequent  
RB pathway lesions in FL
We retrieved an additional cohort of 105 paraffin-embedded 
and arrayed indolent FL samples (patient information for tissue 
second, a highly focal loss centered on the CDKN2a/b locus at 
chromosome 9p21.3 (19 samples: 5%; homozygous: 3%, hetero-
zygous: 2%; Fig. 1, A and B); and third, a loss of 13q14 that in-
cluded the RB1 locus (32 samples: homozygous, 16 [6%]; 
heterozygous, 16 [6%]; Fig. 1, A and B). Quantitative RT-PCR 
confirmed corresponding changes in the mRNA levels of 
CDK4 (P = 0.05), RB1 (P = 0.03), and CDKN2A (P = 0.24; 
Fig. 1, C–E). Hence, a genome-wide analysis of array-CGH data 
representing >250 indolent FLs identifies a mutually exclusive 
relation between focal lesions affecting RB and CDKN2A and 
gains of chromosome 12 that include the RB kinase CDK4.
The CDK4 kinase requires a D-type cyclin for its activity 
toward RB (Matsushime et al., 1992). In our FL cohort, the 
CCND3 expression level is significantly higher than CCND1 
and CCND2 (Fig. 2 A; data deposited in GEO under accession 
no. GSE37088), and Sanger sequencing of 69 samples con-
firmed CCND3 mutations in 6% of FLs (Fig. 2, B and C; and 
Table S3). As reported by Morin et al. (2011), these mutations 
clustered in the PEST domain, they were typically heterozy-
gous, and only one case harbored a homozygous T283A muta-
tion (#107-2124). Similar mutations in the CCND3 PEST 
domain occur in aggressive lymphomas and other cancers 
(Morin et al., 2010, 2011; Musgrove et al., 2011; Pasqualucci 
et al., 2011). The CCND3 mutations co-occur with gains in 
CDK4 in two of four cases (unpublished data), which is con-
sistent with its cofactor function for CDK4/6. Functionally, 
these mutations increase the stability of the CCND3 protein; 
for example, the T283A mutation affects a phosphorylation 
site that is required for proteasomal degradation (Naderi et al., 
2004). Accordingly, cycloheximide treatment of 293T and 
immortalized B cells engineered to express mutant and wild-
type CCND3 confirms increased stability of the mutant 
CCND3 proteins (T283A, V287D, and Q276*; Fig. 2, D–F).
Cell cycle control loci have been implicated in FL trans-
formation (e.g., Elenitoba-Johnson et al., 1998; Pinyol et al., 
1998; Pasqualucci et al., 2014). The UMCN series also in-
cludes 67 transformed FL cases and detailed analysis confirms 
lesions at the CDKN2A locus (18 samples, 17.9% homozygous, 
9% heterozygous), the RB locus (10 samples, 4.5% homozy-
gous, 10.4% heterozygous), and gains of CDK4 in 22 samples 
(Fig. 2 G). This confirms a further increase of RB pathway le-
sions upon transformation.
RB pathway lesions are associated with high-risk disease
The FL international prognostic index (FLIPI; Solal-Céligny 
et al., 2004) provides a prognostic index that reflects parameters 
of disease spread (e.g., stage, number of involved lymph nodes, 
serum lactate dehydrogenase, hemoglobin, and patient age) and 
is predictive of outcome (Solal-Céligny et al., 2004). In the 
MSKCC cohort, 45% of patients were low risk by FLIPI, 26% 
intermediate, and 29% high-risk (FLIPI was not available for 
the UNMC cohort). FLIPI was highly predictive of poor out-
come in our cohort (P = 0.05). We find that genomic lesions 
at cell cycle loci were significantly associated with high risk 
by FLIPI (P = 0.002), and most high-risk tumors by FLIPI 
harbored cell cycle activating lesions (13/17; Table 1, A). The 
Figure 3. TMA analysis for cell cycle control markers in FL identi-
fies a group of P-RB–positive patients. (A–C) Representative TMA 
sections of 105 human FLs stained for CDK4 (A) and CCND3 (CYCLIN D3; 
B). An expanded series of 230 samples was stained for phosphorylated 
RB1 (C). (D) Heat map summary of the IHC stains on human FLs for the 
indicated proteins (negative stain: <20% of positive cells, positive: >20%, 
high: >50% of positive cells). (E) TMA stain for Ki67 in FL (low: <25% of 
positive cells, intermediate: 25–50% of positive cells, high: >50% of posi-
tive cells). (F) Association of high Ki67 stain (Ki67: >50% of cells) with 
expression status (positive/negative) of the indicated proteins (*, P < 0.05). 
(G) Association of high Ki67 stain (Ki67: >50% of cells) with copy number 
alterations affecting the CDKN2A/B, RB1, or CDK4 loci with high Ki67 
stains (*, P < 0.05). P-value was calculated by unpaired Student’s t test.
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pathway activity. In an expanded series of 230 FLs, we ob-
served RB phosphorylation in 46% (106/230) of the arrayed 
indolent FLs (Fig. 3 C), again including most cases with posi-
tive CDK4 FISH and elevated CDK4 and CCND3 protein 
levels (Fig. 3 D). Ki67 marks proliferating cells and is typically 
lower in FLs than in aggressive lymphomas (Llanos et al., 
2001; Martinez et al., 2007). We confirm this in our TMA 
cohort and find that 21% of FLs had >50% Ki67-positive 
staining cells, indicating an extensive growth fraction (Fig. 3 E). 
These included most samples with increased CDK4, CCND3, 
and phosphorylated RB, indicating that loss of RB checkpoint 
microarrays [TMAs] overlap with aCGH cohorts summa-
rized in Table S4). First, our genomic data implicate CDK4 as 
a target of gains in a large percentage of FL. We used CDK4 
FISH to confirm the CDK4 gain in 24.5% of samples, and 
this includes an overlap group where both aCGH and FISH 
showed CDK4 gains (Table S4). This was also reflected at 
the protein level, and the CDK4 and CCND3 proteins were 
abundantly expressed in 67%, including 11 of the 13 CDK4 
FISH-positive tumors (Fig. 3, A and B; and Table S4). CDK4/
CCND3 for the active RB kinase and, accordingly, RB1 
(Ser780) phosphorylation provide a summary readout of 
Figure 4. Cell cycle lesions cooperate with Bcl2 in lymphomagenesis. (A) Diagram of the adoptive transfer model of FL. (B) Kaplan-Meier analysis 
showing time to tumor development after transplantation of vavP-Bcl2 transgenic HPC transduced with vector (black; n = 24) or CDK4 (blue; n = 11 
[CDK4 vs. vector, P = 0.001]), kinase-dead CDK4 (CDK4-KD, gray; n = 6), c-MYC (n = 7) (red), CCND3 T283A (purple; n = 10 [CCND3 T283A vs. vector, P = 
0.05]), and shRNAs against p16 (green; n = 11 [shp16 vs. vector, P = 0.018]) and Rb1 (pink; n = 9 [shRb vs. vector, P < 0.01]). P-value was derived using 
Log-Rank (Mantel-Cox) test. (C) Immunohistochemical analysis of murine lymphomas harboring the indicated genetic changes and high resolution inset. 
(D–G) Immunoblot on lysates of tumors expressing CDK4, CYCLIN D3 T283A, or shRNAs against p16 or Rb.
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RNAs (shRNAs) targeting p16 or Rb1 into vavBcl2 trans-
genic hematopoietic precursors (Fig. 4, D–G). Mice receiving 
HPCs overexpressing CDK4 or mutant CCND3 develop 
tumors with high incidence and short latency compared 
with vector or CDK4 KD, although not as rapidly as c-MYC 
transduced HPCs (CDK4: n = 11, median latency 58 d 
[CDK4 vs. vector, P = 0.001]; CCND3 T283A: n = 10, 
median latency 87 d [CCND3 T283A vs. vector, P = 0.05]; 
vector controls: n = 24, 80% tumor free, CDK4 KD, n = 10, 
100% tumor free [Cdk4 vs. vector, P = 0.001]; c-Myc: n = 7; 
Fig. 4 B). Similarly, knockdown of p16 (n = 11, median latency 
70 d [shp16 vs. vector, P = 0.018]) and knockdown of Rb1  
(n = 9, median latency 70 d [shRb vs. vector, P < 0.01]) 
strongly cooperate with Bcl2 in FL development (Fig. 4 B). 
Similar to the human tumors we analyzed by TMA and 
drives proliferation but is not sufficient in all cases (Fig. 3 F). 
As expected, high Ki67 further corresponded to high risk 
disease by FLIPI (Fig. 3 G). Hence, the IHC data confirm 
functional RB pathway disruption in a large group of indo-
lent FLs.
Contribution of RB pathway lesions  
to BCL2-driven lymphomagenesis
We use a mouse model that recapitulates key aspects of the 
genetics and morphology of FL and is based on the adoptive 
transfer of vav-P-Bcl2 hematopoietic progenitor cells (HPCs; 
Egle et al., 2004; Oricchio et al., 2011; Fig. 4 A). We intro-
duced MSCV vector constructs directing the expression of 
CDK4, a kinase-dead mutant form of CDK4 (CDK4 KD), 
mutant CCND3 (T283A), or c-MYC, and short-hairpin 
Figure 5. CDK4/6 inhibitors is effecting against human FL cells. (A) Summary of genetic data indicating the t(14;18) causing elevated BCL2 and 
genomic lesions activating the cell cycle as oncogenic drivers in a sizeable fraction of FLs. (B) Cell cycle profile of DoHH2 cells after 24 h of treatment with 
PD-0332991 or vehicle (DMSO). (C) Cell cycle profile of DoHH2, Su-DHL-6, Su-DHL-16, and Ly8 and WSU-NHL cell lines treated with PD-0332991 1 and  
2 µM for 24 h. (D) Immunoblot for RB1 phosphorylation (Ser 780) in DoHH2, Su-DHL-6, Su-DHL-16, and Ly8 and WSU-NHL cells treated as indicated.  
(E) Cell cycle profile of DoHH2 cells expressing the RB1 sh treated with PD-0332991 (1 µM) or vehicle (DMSO). Cell cycle analysis has been repeated at 
least three times for each cell line. (F) Immunoblot for indicated proteins on lysates from DoHH2 cells expressing the RB1 shRNAs (sh1 and sh2).
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follicular organization that is best seen in the PNA stain (Fig. 4 C). 
Although transformed c-MYC–expressing vavBcl2 tumors were 
readily cultured and transplantable (5/5), FLs expressing CDK4 
could not be cultured and did not engraft in syngeneic animals 
(0/5; unpublished data). Hence, the cell cycle activating lesions 
act as oncogenic drivers in the BCL2 context in vivo.
The CDK4/6 kinase is a rational target in a subset of FLs
CDK4/6 acts as the RB kinase, and the frequent RB phos-
phorylation in indolent FL implies CDK4/6 as a therapeutic 
immunohistochemistry, tumors expressing CDK4, Cyclin 
D3, or shp16 showed high levels of phosphorylated Rb, were 
more proliferative by Ki67, and had individual mitotic figures 
(Fig. 4 C). Surface marker analysis confirms the B cell lym-
phoma pathology with varying degrees of T cell infiltration 
(unpublished data). c-MYC–expressing tumors resemble 
transformed FLs and are composed of large cells, with loss 
of peanut agglutinin (PNA) staining and a diffuse growth pat-
tern. However, lymphomas harboring cell cycle lesions are 
composed of smaller B cells and maintain variable degrees of 
Figure 6. Synergy between CDK4/6 and BCL2 inhibi-
tion against human FL cells. (A) Viability in a panel of 
human lymphoma lines after 24 h of treatment with ABT-
737; cell lines harboring the translocation t(14;18) are indi-
cated (*, P = 0.001). Error bars represent the standard 
deviation of three independent experiments. (B) Apoptosis 
analysis of WSU-NHL treated with increasing ABT-737 doses 
measuring annexin-positive cells by flow cytometry. (C) Immuno-
blot for caspase 3 and cleaved caspase 3 in WSU-NHL cell 
line treated with increasing ABT-737 doses for 24 h.  
(D) DoHH2, Su-DHL-6, WSU-NHL, and Granta 452 cell apop-
tosis after in vitro treatment with PD-0332991 (1 µM), ABT-
737 (100 nM), both drugs, or DMSO (*, P < 0.01). Error bars 
represent the standard deviation of three independent ex-
periments. (E) IC50 curves for DoHH2, Su-DHL-6, WSU-NHL, 
and Granta-452 cell line treated with PD-0332991, ABT-737 
alone, and with the drug combination. (F) Table summarizing 
the in vitro data. CI is the combination index, and values  
<0.75 indicate drug synergy (details in Materials and meth-
ods). Each experiment has been repeated at least three times, 
and the graphs represent an average of the experiments.
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DISCUSSION
RB pathway lesions in indolent FL
Our analysis identifies a pattern of mutually exclusive ge-
nomic alterations that impact the RB pathway in a sizeable 
fraction of indolent FLs. These include homozygous and het-
erozygous deletions of CDKN2A/p16 and RB, and a large 
region of chromosomal gains on Chromosome 12. The mu-
tually exclusive relationship between losses of CDKN2A, RB, 
and the chromosome 12 amplifications implicate the RB 
kinase CDK4 as a relevant target at Chr. 12q13. Accordingly, 
CDK4 falls within the common minimal region of gain in all 
samples, and this does not rule out important roles for addi-
tional genes at this locus. Cell cycle lesions have been impli-
cated in FL transformation, for example, most recently in 
Pinyol et al. (1998) and Pasqualucci et al. (2014). Individual 
lesions affecting CDKN2A or RB are relatively rare in the in-
dolent disease (Lenz et al., 2008; Morin et al., 2011; Pasqualucci 
et al., 2011). This has led to the assumption that loss of cell 
cycle control mainly occurs upon transformation. However, 
the cumulative frequency of lesions affecting CDKN2A, 
RB1, and CDK4 indicates disruption of this cell cycle check-
point in a sizeable fraction of indolent FLs. This view is 
further supported by abundant RB phosphorylation in up to 
45% of FLs, increased levels of CDK4, and in vivo evidence 
that CDK4, CDKN2A, and RB impact BCL-2–driven FL 
development in vivo.
RB pathway lesions promote FL pathogenesis in vivo
In a murine FL model, all RB pathway lesions cooperate with 
BCL2 in lymphomagenesis. Most likely, RB inactivation 
overrides the growth inhibitory effects of both BCL2 and 
p21 in germinal center B cells (O’Reilly et al., 1996; Vairo 
et al., 1996, 2000; Phan et al., 2005). It is notable that RB inac-
tivation does not lead to histologically transformed FLs in vivo, 
and this is in clear contradiction to enforced MYC expres-
sion. At least in the murine model, RB pathway lesions are 
not sufficient for disease transformation and this argues that 
additional changes contribute to lymphoma progression. It is 
also consistent with a view that RB pathway lesions facilitate 
FL evolution toward the more aggressive disease, and a serial 
analysis on a large cohort will be needed to address this (Bödör 
et al., 2013; Green et al., 2013; Okosun et al., 2014).
RB phosphorylation distinguishes two types of indolent FL 
with different clinical risk and therapeutic requirements
RB phosphorylation provides a facile summary readout of 
all upstream events that can influence the activity of the 
CDK4/CCND RB kinase including genetic and epigenetic 
changes (Sherr, 1996). We find increased RB phosphorylation 
in 45% of indolent FLs, and the number closely corresponds 
to the cumulative frequency of genomic lesions affecting 
CDK4 and CDKN2A. Although equally represented across 
histological grades (except for transformed FL which show 
the expected increase), the RB pathway lesions are strongly 
associated with elevated risk by FLIPI (Solal-Céligny et al., 
2004). PD-0332991 is a selective inhibitor of the RB kinase 
target in this disease (Fig. 5 A). We explored this hypothesis 
in all available t(14;18)-positive lines including DoHH2, 
Su-DHL-6, Su-DHL-16 and Ly 8, Granta-452, and WSU-
NHL. All of these have elevated levels of CDK4, CDK6, and 
RB1 phosphorylation (S780, S795), and DoHH2 has a ho-
mozygous p16 deletion and a MYC gain/translocation, indi-
cating that these changes are required for in vitro growth 
(Grønbaek et al., 2000). Growth or transplantation of primary 
human FLs is not possible (unpublished data). We first treated 
DoHH2, WSU-NHL, Su-DHL6, Su-DHL-16, and Ly8 cells 
with increasing doses of PD-0332991, which caused com-
plete growth arrest, accumulation in G1 phase, and loss of 
RB1 phosphorylation (Fig. 5, B and D). The cytostatic effect 
of PD-0332991 was strictly dependent on RB1 and knock-
down could bypass cell cycle arrest (Fig. 5, E and F). BH3 
mimetic drugs like ABT-737 block BCL2 function by insert-
ing into the BH3-binding groove of anti-apoptotic BCL2 
proteins (Oltersdorf et al., 2005). Accordingly, ABT-737 has 
selective activity t(14;18)-positive lines in DoHH2, WSU-
NHL, Su-DHL-6, SU-DHL-16, and LY8 cells (Fig. 6 A) 
and induces dose-dependent apoptosis by caspase cleavage 
and annexin induction (Fig. 6, B and C). ABT-737 and PD-
0332991 show synergy against human FL-derived lines 
(Fig. 6 D). A detailed analysis of drug interaction based on cell 
viability (Fitzgerald et al., 2006) reveals combination indices 
< 0.75, indicating synergy for DoHH2, Su-DHL6, and 
WSU-NHL (P = 0.001), and an additive drug interaction in 
Granta 452 cells (combination index = 0.86; Fig. 6, E and F).
Next, we tested this synergistic drug interaction against 
xenografted DoHH2 and WSU-NHL lymphomas. In brief, 
xenografted tumors (>10 mm3) were treated with PD-0332991 
(PD: 150 mg/kg, alternate days per os, days 1–16), ABT-737 
(ABT: 50 mg/kg, alternate days, i.v., days 1–16), or both drugs. 
Individually, each drug somewhat restrained tumor growth 
during the treatment course, but residual DOHH2 and 
WSHU-NHL tumors rapidly expanded shortly thereafter. 
Strikingly, the combined treatment (PD: 150 mg/kg; ABT: 
50 mg/kg, on alternate days 1–16) completely abrogated 
growth and caused lasting and complete responses (decrease 
by >95–100%; PD+ABT vs. PD or ABT, P < 0.004; Fig. 7, 
A and B). As expected, PD-0332991 caused complete loss of 
RB1 phosphorylation (Ser780), blocked cells in G1, and re-
duced Ki67 levels in vivo (Fig. 7, C and D). ABT-737 pro-
duced significant cell death by caspase cleavage, TUNEL stain, 
and annexin FACS (Fig. 7, E and G). We also tested PD-0332991 
against primary mouse lymphomas because we noticed that 
these tumors spontaneously up-regulated CDK4 and CCND3 
(Fig. 7 H). Consistent with the human data, we observed 
powerful therapeutic activity in these primary, indolent lym-
phomas (Fig. 7 I). At an effective combination dose (150 and 
50 mg/kg) we did not observe toxicity, weight loss, organ 
damage, or changes in serum chemistry, and only temporary 
reductions in lymphocytes and platelet counts (unpub-
lished data). Together, the results indicate a therapeutic win-
dow and significant activity of combined RB kinase and 
BCL2 inhibition in FL disease models.
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The cytostatic activity of PD-0332991 strictly depends on 
phosphorylated RB and the drug is inactive in its absence 
(Michaud et al., 2010). Therapeutic studies on indolent FLs 
are limited by lack of tractable models; notably, all FL cell lines 
CDK4/6 and is currently in clinical trials against several cancers, 
including mantle cell lymphoma, but patients with indolent FL 
have been specifically excluded (e.g., http://clinicaltrials.gov/ 
show/NCT01111188; Fry et al., 2004; Flaherty et al., 2012). 
Figure 7. Dual RB kinase and BCL2 inhibition is safe and effective against xenografted FL cells. (A and B) Tumor volume curve for xenografted DoHH2 
and WSU tumors treated with the indicated drugs for 20 d (five or six animals have been used in each treatment group). Error bars represent the standard devia-
tions. (C) Immunoblot on lysates of tumors treated in vivo with PD-0332991 probed for RB1 phosphorylation (Ser780). (D) Cell cycle profile of tumors treated in vivo 
with vehicle or PD 0332991+ABT-737. (E) Immunoblot on lysates of tumors treated in vivo with ABT-737 cleaved caspase-3 (D). (F) Apoptosis analysis of tumors 
treated in vivo with vehicle or PD 0332991+ABT-737. (G) Immunohistochemical analysis of DoHH2 tumors harvested at the end of the treatment interval. (H) West-
ern blot analysis of CDK4, CCND3, and phosphorylated RB expression in splenic B cells of vav-Bcl2 mice before and after spontaneous FL development. (I) Combined 
in vivo treatment of primary murine vavbcl2 lymphomas with combination of PD-0332991 and ABT-737 produces disease response quantified by blood counts.
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represent the transformed state and carry cell cycle lesions 
similar to those seen in the human tumors. However, across 
the best available human models (DoHH2 and WSU-NHL), 
we find that PD-0332991 alone is mostly cytostatic, and that 
combinations with BCL2-inhibiting drugs (e.g., ABT-737 
[Oltersdorf et al., 2005] or obatoclax) are synergistic in vitro 
and at least additive against xenografts in vivo and with ac-
ceptable toxicity. Together, we report the surprising observa-
tion of frequent and mutually exclusive RB pathway lesions 
(CDK4, CDKN2a/p16, RB, and CCND3) at the indolent 
stage of FL that is reflected in the RB phosphorylation state 
and identifies a high-risk group of FL patients who may ben-
efit from CDK-directed therapies.
MATERIALS AND METHODS
Tumor ascertainment. Newly diagnosed FLs collected at MSKCC since 
1985 and evaluated by 3 hematopathologists were classified according to 
WHO criteria as nontransformed FL.
Array-CGH. DNA from fresh frozen tissue or OCT-embedded was isolated 
and processed as previously described (Oricchio et al., 2011). In brief, label-
ing and hybridization was performed according to protocols provided by 
Agilent Technologies. Before submission to the Genomics core for labeling 
and hybridization to the 244K oligonucleotide array (Agilent Technologies), 
digestion efficiency of each DNA was checked by incubating 1 µg DNA 
with 1 µl HaeIII (10 U/µl) at 37°C for 2 h, and running in parallel the undi-
gested and digested DNA (100 ng each) on a 1% agarose gel along with 
the 1 kb DNA ladder. Human male DNA (Promega) served as the reference 
DNA. Labeling and hybridization were performed according to protocols 
provided by Agilent Technologies. The slides were scanned at 5-µm resolu-
tion using the G2565 Microarray Scanner System (Agilent Technologies), 
and Feature Extraction software (v9.1; Agilent Technologies) was used to 
generate the data. Data are available on GEO under accession no. GSE40989. 
Copy Number Data from a second dataset (UNMC dataset) has been gener-
ated using GeneChip Human Mapping 250K Nsp SNP array (Affymetrix) as 
described in Bouska et al. (2014).
Copy number analysis. To identify significantly amplified and deleted re-
gions, we used the GISTIC algorithm (Beroukhim et al., 2010) through the 
GenePattern web service (http://genepattern.broadinstitute.org). GISTIC 2.0 
(Beroukhim et al., 2010; Mermel et al., 2011) has been run on segmented 
copy number data generated for each dataset using the DNAcopy package 
from Bioconductor (Olshen et al., 2004). Recurrently amplified and deleted 
regions were selected if q < 0.05 or residual q < 0.1 (Beroukhim et al., 2010). 
Peaks identified by GISTIC span a variable number of genes (varying be-
tween 1 and 200). To focus on cancer-relevant genes in these regions, we 
intersected the set of genes from these regions with the Sanger Cancer Cen-
sus gene list (Futreal et al., 2004). Both the full and cancer-specific list of 
genes contained in each region is provided in Table S2.
Next, we compared the two sets of GISTIC regions to identify which and 
how many regions determined on one dataset have at least one matching region 
in the other. Regions were considered matching if the corresponding peaks 
were overlapping or at maximum 5 MB apart. Overall, 67% of the regions from 
the MSKCC dataset have a match in the UNMC dataset and 46% of regions from 
the UNMC dataset have a match in the MSKCC dataset. Notably, all the most 
significant regions from the two datasets (residual q < 14) are matched.
Mutual exclusivity analysis. To identify a significant mutually exclusive 
pattern of copy number alteration we used the algorithm MEMo (Ciriello et al., 
2012). In brief, MEMo used as input the set of gene peaks of gain and loss we 
derived from the array-CGH analysis. Alterations targeting fully connected 
gene sets were tested for mutual exclusivity based on a random permutation 
of the observed genomic alterations. Genomic events were permuted using 
a Monte Carlo Markov Chain approach that preserves both the number of 
alteration per gene and the number of alterations per sample.
CCND3 sequencing and PCR amplification. The exonic regions of 
interest (NCBI Human Genome Build 36.1) were broken into amplicons of 
350 bp or less, and specific primers were designed using Primer 3 to cover the 
exonic regions plus at least 50 bp of intronic sequences on both sides of intron-
exon junctions (Rozen and Skaletsky, 2000). M13 tails were added to facilitate 
Sanger sequencing. PCR reactions were performed in 384-well plates, in a 
Duncan DT-24 water bath thermal cycler, with 10 ng of template DNA 
(Repli-G Midi; QIAGEN) as template, using a touchdown PCR protocol 
with Kapa2G Fast HotStart Taq (Kapa Biosystems). The touchdown PCR 
method consisted of: 1 cycle of 95°C for 5 min; 3 cycles of 95°C for 30 s, 64°C 
for 15 s, and 72°C for 30 s; 3 cycles of 95°C for 30 s, 62°C for 15 s, and 72°C 
for 30 s; 3 cycles of 95°C for 30 s, 60°C for 15 s, and 72°C for 30 s; 37 cycles 
of 95°C for 30 s, 58°C for 15 s, and 72°C for 30 s; and 1 cycle of 70°C for 
5 min. Templates were purified using AMPure (Beckman Coulter). The puri-
fied PCR reactions were split into two and sequenced bidirectionally with 
M13 forward and reverse primer and Big Dye Terminator kit (v.3.1; Applied 
Biosystems) at Beckman Coulter Genomics. Dye terminators were removed 
using the CleanSEQ kit (Beckman Coulter), and sequence reactions were run 
on an ABI PRISM 3730xl sequencing apparatus (Applied Biosystems).
CCND3 mutation detection. Mutations were detected using an automated 
detection pipeline at the MSKCC Bioinformatics Core. Bi-directional reads 
and mapping tables (to link read names to sample identifiers, gene names, 
read direction, and amplicon) were subjected to a QC filter which excludes 
reads that have a mean phred score of <10 for bases 100–200. Passing reads 
were assembled against the reference sequences for each gene, containing all 
coding and UTR exons, including 5 Kb upstream and downstream of the 
gene, using command line Consed 16.0 (PMID: 9521923). Assemblies were 
passed on to Polyphred 6.02b (PMID: 9207020), which generated a list of pu-
tative candidate mutations, and to Polyscan 3.0 (PMID: 17416743), which 
generated a second list of putative mutations. The lists were merged together 
into a combined report, and the putative mutation calls were normalized 
to + genomic coordinates and annotated using the Genomic Mutation Con-
sequence Calculator (PMID: 17599934). The resulting list of annotated puta-
tive mutations was loaded into a Postgres database along with select assembly 
details for each mutation call (assembly position, coverage, and methods sup-
porting mutation call). To reduce the number of false positives generated by 
the mutation detection software packages, only point mutations which are 
supported by at least one bi-directional read pair and at least one sample muta-
tion called by Polyphred were considered, and only the putative mutations, 
which are annotated as having nonsynonymous coding effects, occur within 
11 bp of an exon boundary, or have a conservation score >0.699 were in-
cluded in the final candidate list. Indels culled by any method were manually 
reviewed and included in the candidate list if found to hit an exon. All putative 
mutations were confirmed by a second PCR and sequencing reaction; matched 
normal tissue DNA was not available but the reported mutations have never 
been seen as normal variation (1000 Genomes Project Consortium et al., 
2012). All traces for mutation calls were manually reviewed.
Gene expression array and analysis. Affymetrix U133A gene chips were 
used for gene expression profiling of 72 FL samples. The transcriptome analy-
ses were performed using RMA system software packages (version 2.8.0) in-
cluding Bioconductor (version 2.0). Raw gene expression data from 
Affymetrix CEL files were analyzed using the affy R library from Biocon-
ductor to generate probe level intensity. Gene-centric expression values were 
generated using a CDF file based on remapping of probes to the human 
genome 36.1. The raw data for 72 FL patient samples (CEL file) and the nor-
malized matrix have been deposited in GEO (GSE37088).
Clinical data analysis. Collection of clinical information of all FL cases is 
under MSKCC IRB waiver approval. Clinical data for UNMC are available 
in (Bouska et al., 2014). Statistical methods: the association between the 
JEM Vol. 211, No. 7 
Article
1389
WSU-NHL were maintained in RPMI 1640 with 10% fetal bovine serum, 
1% l-Glutamine, and 1% penicillin/streptomycin. Human lymphoma cell 
lines treated with PD-0332991 and ABT-737 were analyzed for cell viability 
and cell cycle assays. In brief, cells were seed at 5 × 105/ml and they were 
treated with PD-0332991 and/or ABT-737. After 24 h of treatment, cell via-
bility was assessed using CellTiterGlo reagent (Promega). The data were ana-
lyzed for drug interactions and the Combination Index (CI) was calculated as 
reported in Fitzgerald et al., (2006).
Western blot and flow cytometry analysis. Immunoblots were performed 
from whole cell lysates or tissue samples as previously described (Wendel et al., 
2004). In brief, 30 µg protein/sample was resolved on SDS-PAGE gels and 
transferred to Immobilon-P membranes (Millipore). Antibodies were against 
Rb (Cell Signaling Technology), Phospho-Rb S780 (Cell Signaling Technol-
ogy), Phospho-Rb S795 (Cell Signaling Technology), CDK4 (Cell Signaling 
Technology), Cyclin D3 (Cell Signaling Technology), Cyclin D1 (Cell Signal-
ing Technology), Cyclin D2 (Cell Signaling Technology), p16 (Santa Cruz 
Biotechnology, Inc.), Caspase 3 (Cell Signaling Technology), and Tubulin 
(1:5,000; Sigma-Aldrich). Enhanced chemiluminescence was used for detec-
tion (ECL; GE Healthcare). Cell cycle profile and apoptosis analyses has been 
performed using Guava Cell Cycle reagent (Millipore) Guava Nexin reagent 
(Millipore) and expression was assessed through FACS analysis (Guava Easy-
Cyte; Millipore). Experiments have been performed three times or more.
Generation of mice. The vavP-Bcl2 mouse model of FL (Egle et al., 2004) 
was adapted to the adoptive transfer approach using retrovirally transduced 
HPCs (Wendel et al., 2004). In brief, we isolated vavPBcl2 transgenic fetal 
liver cells from vavPBcl2 heterozygous animals at embryonic day 13.5 (E13.5). 
The HPCs are grown for 4 d in a specially adapted growth medium contain-
ing IL3, stem cell factor, and IL6 and are retrovirally transduced with MSCV 
vectors directing the expression of genes or shRNAs of interest. We trans-
plant genetically modified HPCs into lethally irradiated, syngeneic wild-type 
recipients and monitor disease onset weekly by palpation. Data were analyzed 
in Kaplan-Meier format using the log-rank (Mantel-Cox) test for statistical 
significance. All experiments were approved by the MSKCC IACUC com-
mittee (protocol #07–01-002). Plasmids expressing human short hairpins for 
RB1 and overexpressing CDK4 were provided by A. Chicas, S. Lowe, and 
D. Ciznadid (MSKCC, New York, NY).
Online supplemental material. Table S1 shows array-CGH analysis of 64 
(MSKCC dataset) and 198 (UNMC dataset) FLs. Table S2 shows a summary 
of genome-wide mutually exclusive analysis in 292 FLs. Table S3 shows a 
summary of reported Cyclin D3 mutations in lymphoma. Table S4 shows a 
summary of aCGH, FISH, and IHC analyses for CDK4, Cyclin D3, and RB 
in our FL cohorts. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20132120/DC1.
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alteration in cell cycle genes (binary yes/no) and GRADE and FLIPI were 
compared using Fisher’s exact test. FLIPI model 2004 has been used to clas-
sified FL patients (Solal-Céligny et al., 2004). Overall survival is summarized 
using Kaplan-Meier curves and tests of association between the categorical 
variables (alteration, GRADE, and FLIPI).
Immunohistochemical and TMA methods. TMAs were constructed 
as previously published (Schatz et al., 2011), but using a fully automated 
Beecher Instrument, ATA-27. The study cohort was comprised of FL con-
secutively ascertained at MSKCC between 1985 and 2000. Additional clini-
cal details are listed in Table S1. Use of tissue samples was approved with an 
Institutional Review Board Waiver and approval of the Human Biospeci-
men Utilization Committee. All cancer biopsies were evaluated at MSKCC, 
and the histological diagnosis was based on hematoxylin and eosin (H&E) 
staining. TMAs were stained with the P-Rb (Ser780) and Cyclin D3 anti-
body (1:500; Cell Signaling Technology), with CDK4 (DCS-31; 1:500; 
Invitrogen), and with Ki67 and Ventana Discovery XT, using protocol 67: 
CC1, standard, at 1:100 dilution overnight at 4°C, and then with a sec-
ondary anti–rabbit antibody (Vector Laboratories) at 1:200 dilution for 60 min. 
The negative controls were performed on the same slides as the FL-TMAs. 
Each slide with TMA spots also had spleen, kidney, and/or lymph node 
controls. Breast cancer and sarcoma samples have been used as positive stain-
ing control. Positive score is defined with >20% of cells expressing CDK4, 
Cyclin D3, and P-RB; negative score for samples with 0–20% of signal and 
high levels in samples with >50% of positive cells.
Fluorescence in situ hybridization. FISH was performed using BAC 
clones spanning CDK4 in 12q13: RP11-571M6 (part of a 1Mb clone set 
supplied by the Wellcome Trust Sanger Institute) and RP11-970A5 (from 
BACPAC resources, Children’s Hospital at Oakland Research Center). The 
BACs were labeled by nick translation with Red-dUTP (Enzo Life Sciences, 
supplied by Abbott Molecular, Inc.), and hybridized with chromosome 
12 centromeric repeat p12H8, labeled with Orange-dUTP, as reference. 
The baseline autofluorescence of many tumor cores was quite high, and the 
orange dye was used instead of the more usual Green-dUTP in an attempt to 
improve probe visibility. The TMA slides were hybridized according to stan-
dard procedures. In brief, the slides were dewaxed, microwaved in 10 mM 
sodium citrate buffer, pH 6.0, and treated with pepsin-HCl. Slides with probe 
mix were co-denatured on a HYBrite automated hybridizing station (Abbott 
Molecular Inc.) at 80°C for 8 min, and then incubated for 2–3 d at 37°C. 
After coverslip removal, the slides were washed using standard nonformamide 
stringency washes, stained with DAPI, and then mounted in antifade solution 
(VECTASHIELD; Vector Laboratories). The slides were scanned at low reso-
lution using a Metafer MetaCyte automated scanning system (Metasys-
tems Group Inc.), comprised of an epifluorescence microscope (Axioplan 
2i; Carl Zeiss) equipped with a megapixel charge-coupled device camera 
(CV-M4+CL, JAI) and motorized stage (Martzhauser). The scanned image 
was then segmented into individual cores using the MetaCyte TMA tool, and 
high-resolution compressed image z-stacks (9 × 0.5 µm) were captured using 
FISH imaging software (5.2; Isis). Orange signals were pseudocolored in 
green for clarity, and CDK4 and reference signals were counted for each 
image and the ratio calculated for each core.
Xenografts and treatment studies. Xenografts and treatment studies were 
generated as previously described (Schatz et al., 2011). In brief, s.c. injection of 
5 Mio DoHH2 and WSU-NHL human lymphoma cells mixed with Matrigel 
(BD) into the flanks of mice NOD/SCID (NOD.CB17-Prkdcscid/J). Upon 
tumor size, 100-mm3 mice were treated daily by gavage with 150 mg/kg PD-
0332991 (Chemitek) diluted in 50 mmol/liter sodium lactate, pH 4, for 2 wk 
and with ABT-737 50 mg/kg dilute in PTD solution (30% propylene glycol, 5% 
Tween 80, and 65% D5W). The control animals were treated with 50 mmol/
liter sodium lactate, pH 4, PTD solution, and 5% Dextrose in water solution, re-
spectively. Tumors were weighed and volumes were measured twice weekly.
Cell culture, cell cycle, and viability assays. Lymphoma cell lines 
DoHH2, Ly-8, Su-DHL-6, Su-DHL-16, Su-DHL-8, and Su-DHL-10 and 
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